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Sir,
I read with interest the article by Cold et al (2005) in the 19
September issue. The authors reviewed the database of the Danish
Breast Cancer Cooperative Group (DBCG), including 7501 patients
with early breast cancer who received adjuvant chemotherapy
between 1977 and 1999. The patients have been divided into three
groups according to the regimen, which were oral CMF (oral
cyclophosphamide, methotrexate, 5-fluorouracil), intravenous CMF,
and CEF (cyclophosphamide, epirubicin, 60mgm
2,5 - f l u o r o u r a c i l )
comprising 352, 6065, and 1084 patients, respectively. No significant
benefit was observed in patients who had received the first cycle
within 21 days after surgery comparatively to those who received it
between 22–28 days, 29–35 days, or 36–89 days. Nevertheless, this
study deserves some comments. Most of the patients have been
treated before 1998 and historically, only patients with large
tumours were eligible for chemotherapy. Given toxicity, most of
the patients were young such as illustrated in the cohort treated with
classical CMF. Thus, patients with a high risk of resistance to
chemotherapy have been selected. In this line, we cannot agree with
the argument that the NSABP-B28 trial has demonstrated no
improvement in terms of disease-free survival since neoadjuvant
chemotherapy has been initially developed to avoid mastectomy in
patients with large tumours. Recently, the Aberdeen trial of
sequential neoadjuvant chemotherapy with anthracyclins followed
by docetaxel has clearly revealed a subpopulation resistant to both
drugs (Smith et al, 2002). This phenomenon has been illustrated in
the setting of preoperative chemotherapy of non-small-cell lung
cancer in which the benefit is predominant in stages I and II
(Depierre et al, 2002). Moreover, we must point to the fact that most
of the Danish patients have received suboptimal regimen since it is
widely admitted that CMF is inferior to three-drugs regimen
including an anthracyclins (Early Breast Cancer Trialists Collabora-
tive Group, 2005; Levine et al, 2005). The CEF60 regimen also is
probably inferior to either CAF50 (cyclophosphamide, doxorubicin,
50mgm
2, 5-fluorouracil) or CEF100 (Piccart et al, 2001; Bonneterre
et al, 2005). Another point is the limit of the statistical analysis
secondary to the segmentation of the database into three distinct
studies according to the chemotherapy regimen. Thus, for example,
no conclusion should be drawn from the small population of 352
patients treated with classical CMF. Moreover, the oestrogen-receptor
status was unknown in a large fraction of this subpopulation. The
subpopulation of patients treated with CEF also is relatively limited.
The comparison between perioperative chemotherapy and adjuvant
chemotherapy might be discussed since the tumour cell populations
probably are different in the two situations. The authors point that
the benefit obtained by perioperative chemotherapy seems to
disappear when patients receive classical adjuvant chemotherapy
(van der Hage et al, 2001). This opinion might result from a
misinterpretation of the experimental studies conducted during the
80s. In murine models, removal of a primary tumour increases the
labelling index and angiogenesis of the distant micrometastases
(Fisher et al, 1983; Folkman, 1990). The crucial data revealed by these
studies are the timing of these mechanisms, which principally occur
from D1 to D3 after surgery, then decrease rapidly from D4 to D7.
Thus, the delay of 21 days is purely arbitrary and is supported by no
biological argument. A meta-analysis of five trials using the
suboptimal CMF regimen administered within 72h after surgery
has demonstrated an absolute benefit of 3.4% in terms of disease-free
survival for patients treated within this delay (Clahsen et al, 1997).
Moreover, another fundamental data that has been omitted by the
authors are the release of circulating cells by tumour removal (Brown
et al, 1995). In this line, we also might address the question of the
possible release of circulating cells during biopsy, which could lead to
ac o n s i d e r a b l ei n c r e a s ei nt h ed e l a yt os y s t e m i ct h e r a p y .A f t e r
d i s s e m i n a t i o n ,t h ep r o g n o s i sm i g h tb ec o m p r o m i s e ds i n c eB r a u net al
(2000) have demonstrated that adjuvant administration of neither
anthracyclins nor taxanes can eradicate micrometastases in the bone
marrow. Resistance can be due to molecular mechanisms such as
multidrug resistance but also by cell dormancy. Moreover, the
stromal environment might promote tumour growth and resistance
to chemotherapy as demonstrated in multiple myeloma (Nefedova
et al, 2003). Thus, comparison between perioperative and adjuvant
probably is not pertinent. Finally, perioperative chemotherapy should
not be dissociated from neoadjuvant chemotherapy, which can be a
predictive factor of response to our increasing number of active
drugs. In conclusion, this study might support a confusion by
comparing the optimal delay of perioperative chemotherapy, which
tends to optimise systemic therapy, and the tolerable delay of classical
adjuvant therapy, which evaluates the impact of limitations in
medical resources (Altundag ˘ et al, 2000). Published online 7 March 2006
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